CHRAC1

Across TCGA pan-cancer cohorts, CHRAC1 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of CHRAC1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CHRAC1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CHRAC1 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

HNSC, THCA, and KIRC are the cancer types where CHRAC1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CHRAC1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	III,IV	+1.306	<.001	12	view →
THCA	All	II,III,IV	−0.398	<.001	10	view →
KIRC	All	All	+0.245	<.001	10	view →
LIHC	Male	II,III,IV	+1.331	<.001	9	view →
LUSC	All	III,IV	+0.905	<.001	9	view →
STAD	Male	II,III,IV	+0.906	<.001	6	view →
COAD	Male	II,III,IV	+0.466	.001	6	view →
BRCA	All	II,III,IV	+0.388	<.001	6	view →
LUAD	All	III,IV	+0.328	.012	4	view →
CHOL	Male	All	+1.811	<.001	3	view →
BLCA	Female	All	+0.365	.012	3	view →
KICH	Male	IV	+0.833	<.001	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

CHRAC1–HNSC

Open the HNSC breakdown →